melanotan 1 vs melanotan 2: Frequently asked questions

Melanotan-2 produces visible tanning 40–50% faster than Melanotan-1 at equivalent pigmentation endpoints, but that speed comes with systemic side effects most users underestimate. If speed is critical and side effects are manageable, start Melanotan-2 at 0.1–0.2mg subcutaneous daily and titrate upward no faster than 0.1mg per week. This minimises nausea and cardiovascular effects while allowing melanogenesis to progress. Pair it with structured UV exposure (5–10 minutes per session, 2–3 times weekly) to maximise pigment deposition without excessive peptide dosing.

Reduce the dose by 50% or switch to Melanotan-1. Spontaneous erections occur because Melanotan-2 binds MC4R in the hypothalamus and spinal cord. The same pathway activated by bremelanotide, an FDA-approved sexual dysfunction drug. Lowering the dose to 0.25mg or less reduces MC4R activation while preserving some MC1R-mediated pigmentation, but this also slows tanning significantly. For pigmentation-focused research without sexual side effects, Melanotan-1 is the mechanistically appropriate choice. Its 1,000-fold lower MC4R affinity eliminates this pathway entirely.

Discard it immediately. Cloudiness indicates bacterial contamination, protein aggregation, or improper lyophilisation. None of which are salvageable. Melanotan-1 and Melanotan-2 should reconstitute into a clear, colourless solution when mixed with bacteriostatic water. Any deviation from clarity suggests the peptide has degraded or been contaminated during storage, shipping, or reconstitution. For research-grade peptides like those available through Real Peptides, third-party purity verification (HPLC, mass spec) is standard. Unregulated suppliers rarely provide this.

Reduce your dose by 50% and extend the titration schedule. Inject every third day instead of daily. Nausea from melanocortin peptides is mediated by MC4R activation in the area postrema (the brain region that detects toxins in blood). It's dose-dependent and transient, typically resolving within 90–120 minutes post-injection. If nausea persists beyond four hours or includes vomiting, discontinue the current dose entirely and resume at half the previous amount after 48 hours. Pre-dosing with 10mg domperidone 30 minutes before injection can block MC4R-driven nausea without interfering with MC1R tanning effects, but this requires prescriber consultation.

Melanin pigmentation fades slowly. Eumelanin has a turnover rate of 14–21 days in epidermal keratinocytes. Missing one week of maintenance dosing will not cause immediate pigmentation loss, but skipping two consecutive weeks typically results in 20–30% reduction in tan intensity as melanocytes downregulate melanogenesis in the absence of continued MC1R stimulation. To re-establish baseline, resume maintenance dosing immediately without loading. Loading protocols are only required when starting from zero pigmentation. Missing doses during the initial loading phase is more problematic because MC1R receptor density is still upregulating; gaps longer than 72 hours during loading may require restarting the titration schedule from the beginning.

Discard it immediately. Lyophilised peptides should reconstitute into clear, colourless solutions. Cloudiness indicates protein aggregation. Either from improper storage before reconstitution (temperature above −20°C), contamination during mixing, or expired product. Aggregated peptides are biologically inactive and potentially immunogenic. This is not a cosmetic issue you can inject through. The mechanism: melanocortin peptides fold into specific three-dimensional conformations that fit MC1R binding pockets; aggregation destroys that conformation, rendering the peptide unable to trigger downstream signalling cascades regardless of dose.

Melanotan-1 is the only viable option. Melanotan-2's MC4-mediated cardiovascular effects. Transient systolic blood pressure elevations of 10–20 mmHg, heart rate increases of 5–15 bpm, and facial flushing. Occur in 30–40% of subjects at therapeutic doses and require serial blood pressure monitoring and exclusion of participants with pre-existing hypertension. Melanotan-1 produces no clinically significant cardiovascular changes in Phase 3 trials, allowing researchers to proceed without continuous hemodynamic surveillance. This distinction is critical in field studies, remote administration protocols, or populations where frequent clinical assessment is impractical.

Melanotan-2 becomes the peptide of interest. Its broad melanocortin receptor activity. Particularly MC4 agonism. Produces measurable reductions in food intake, body weight, and adiposity in both animal and human models. A 2002 study in Diabetes demonstrated that Melanotan-2 at 0.025mg/kg reduced 24-hour caloric intake by 22% and produced 2.1 kg mean weight loss over 14 days in obese men. These effects do not occur with Melanotan-1 because MC1 receptors on melanocytes do not regulate energy balance. Researchers investigating melanocortin pathways in obesity, insulin resistance, or thermogenesis require Melanotan-2's multi-receptor engagement. The melanogenesis is a secondary effect rather than the primary endpoint in these protocols.

Select Melanotan-1. Its MC1 receptor selectivity produces dose-dependent increases in melanin density (quantifiable via reflectance spectrophotometry) without engaging MC4 receptors in the hypothalamic satiety centers. Studies published in Pigment Cell & Melanoma Research confirm that Melanotan-1 at 0.016mg/kg daily produces measurable tanning within 10 days with no statistically significant change in food intake, body weight, or self-reported hunger scores. Melanotan-2 would confound these endpoints. MC4 agonism reduces caloric intake by 15–30% in rodent models and produces subjective appetite suppression in human trials, making it unsuitable when melanogenesis is the isolated variable.